EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Bayer

Status: Completed

Conditions: Macular Degeneration

Treatments: Drug: Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT01756248

EYL-AMD (Other Identifier)

15895

Details and patient eligibility

About

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).

The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice.

A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.

Enrollment: 3,872 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who received EYLEA for AMD

Exclusion criteria

• Patients who have already received EYLEA

Trial design

3,872 participants in 1 patient group

Group 1

Treatment:

Drug: Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)